• 1
    Anonymous. A new clinical entity Br Med J 1956; 1:78990.
  • 2
    Behan PO, Behan WMH, Bell EJ. The postviral fatigue syndrome-an analysis of the findings in 50 cases. J Infect 1985; 10:21122.
  • 3
    Straus SE, Tosato G, Armstrong G, Lawley T, Preble OT, Henle W, Davey R, Pearson G, Epstein J, Brus I, Blaese RM. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985; 102:716.
  • 4
    Lloyd AR, Wakefield D, Boughton CR, Dwyer JM. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust 1989; 151:1224.
  • 5
    Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28:140310.
  • 6
    Wakefield D, Lloyd A. Pathophysiology of myalgic encephalomyelitis. Lancet 1987; ii:9189.
  • 7
    Kronfol Z, Silva J Jr, Greden J, Dembinski S, Gardner R, Carroll B. Impaired lymphocyte function in depressive illness. Life Sci 1983; 33:2417.
  • 8
    Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M. Lymphocyte function in major depressive disorder. Arch Gen Psychiatry 1984; 41:4846.
  • 9
    Schleifer SJ, Keller SE, Bond R, Cohen J, Stein M. Major depressive disorder and immunity. Arch Gen Psychiatry 1989; 46:817.
  • 10
    Hickie I, Silove D, Hickie C, Wakefield D, Lloyd A. Is there significant immune dysfunction in depressive disorders Psychol Med 1990; 20:75561.
  • 11
    Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with chronic fatigue syndrome. Br J Psychiatry 1990; 156:53440.
  • 12
    Dalgleish A. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust 1990; 152:50.
  • 13
    Hickie I, Parker G, Wilhelm K, Tennant C. (1991a) Perceived interpersonal risk factors to non-endogenous depression. Psychol. Med 1991; 21:399412.
  • 14
    Lloyd AR, Wakefield D, Boughton CR, Dwyer JM. What is myalgic encephalomyelitis Lancet 1988; i:12867.
  • 15
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (3rdedn. rev.) 1987. Washington , DC : American Psychiatric Association.
  • 16
    Goldberg DP. Manual of the General Health Questionnaire. 1979. Windsor : NFER Publishing Co.
  • 17
    Jackson A, Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leucocytes. In: RoseN, FriedmanH, FaheyJ, eds. Manual of Clinical Laboratory Immunology. 1986. p. 226. Washington DC : American Society of Microbiology.
  • 18
    Kniker W, Anderson C, McBryde J, Roumiantzeff M, Lesourd B. Multitest CMI for standardised measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the USA. Ann Allergy 1984; 52:7582.
  • 19
    Maluish A, Strong D. Lymphocyte proliferation. In: RoseN, FriedmanH, FaheyJ, eds. Manual of Clinical Laboratory Immunology. 1986; p. 274. Washington DC : American Society of Microbiology.
  • 20
    Arnold DL, Bore PJ, Radda GK, Styles P, Taylor DJ. Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post viral exhaustion/fatigue syndrome. A 31P nuclear magnetic resonance study. Lancet 1984; i:13679.
  • 21
    Hamblin TJ, Hussain J, Akbar AN, Tank YC, Smith JL, Jones DB. Immunological reasons for chronic ill-health after infectious mononucleosis. Br Med J 1983; 287:859.
  • 22
    Lloyd AR, Hickie I, Boughton CR, Spencer O, Wakefield D. Prevalence of chronic fatigue syndrome in an Australian population. Med J Aust 1990; 153:5228.
  • 23
    Rouse B, Horohov D. Immunosuppression in viral infections. Rev Infect Dis 1986; 8:85073.
  • 24
    Haider S, Coutinho M, de L, Emond RTD, Sutton RNP. Tuberculin anergy and infectious mononucleosis. Lancet 1973; ii:74.
  • 25
    Caliguiri M, Murray C, Buchwald D, Levine H, Cheney P, Petersen D, Komaroff AL, Ritz J. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139:330613.
  • 26
    Morrison LJA, Behan WMH, Behan PO. Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin Exp Immunol 1991; 83:4416.
  • 27
    Schattner A, Meshorer A, Wallach D. Involvement of interferon in virus-induced lymphopenia. Cell Immunol 1983; 79:1125.
  • 28
    Einhorn S, Blomgren H, Einhorn N, Strander H. In vitro and in vivo effects of interferon on the response of human lymphocytes to mitogens. Clin Exp Immunol 1983; 51:36977.
  • 29
    Toy JL. The interferons. Clin Exp Immunol 1983; 54:113.
  • 30
    McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha interferon in hepatitis B carriers. Lancet 1987; ii:11759.
  • 31
    Breder CD, Dinarello CA, Saper CB. Interieukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240:3213.
  • 32
    Lloyd AR, Hales JP, Gandevia SC. Muscle strength, endurance and recovery in the post-infection fatigue syndrome. J Neurol Neurosurg Psychiatry 1988; 51:131622.
  • 33
    Lloyd AR, Gandevia SC, Hales JP. Muscle endurance, twitch properties, voluntary activation and perceived exertion in normal subjects and patients with chronic fatigue syndrome. Brain 1991; 114:8598.
  • 34
    Riley MS, O'Brien CJ, McCluskey DR, Bell NP, Nicholls DP. Aerobic work capacity in patients with chronic fatigue syndrome. Br Med J 1990; 301:9536.
  • 35
    Hickie I, Hickie C, Lloyd A, Silove D, Wakefield D. Impaired cell-mediated immunity in patients with melancholia. Am J Psychiatry 1991; (submitted).